Reduce drooling and improve swallowing
- Trial ID
- NCT04664634
- Official Title
- A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
- Goal
- Reduce drooling and improve swallowing
- Phase
- PHASE3
- Status
- RECRUITING
- Sponsor
- Northwestern University
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Dysphagia, Parkinson Disease
- Interventions
- Aria Sensor
Plain-Language Summary
Aims to reduce drooling and improve swallowing safety and control for people with Parkinson's who have mild to moderate sialorrhea. It uses the Aria Sensor, a wearable digital therapeutic platform that senses swallowing and saliva events and delivers real-time feedback and guided exercises to help retrain swallowing and saliva management, working alongside your usual Parkinson's medications rather than replacing them. Assessments are done while you are in the "on" phase of your medication so results reflect your best motor function. Looking for English-speaking adults 22 and older with idiopathic Parkinson's at any Hoehn and Yahr stage, a ROMP-Saliva C score of 11 or higher, ability to use the sensor, and no recent aspiration pneumonia, active drooling treatments, feeding tubes, or certain allergies.
Locations
- Northwestern University, Evanston, Illinois, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aria Sensor. Aims to reduce drooling and improve swallowing safety and control for people with Parkinson's who have mild to moderate sialorrhea. It uses the Aria Sensor, a wearable digital therapeutic platform that senses swallowing and saliva events and delivers real-time feedback and guided exercises to help retrain swallowing and saliva management, working alongside your usual Parkinson's medications rather than replacing them. Assessments are done while you are in the "on" phase of your medication so results reflect your best motor function. Looking for English-speaking adults 22 and older with idiopathic Parkinson's at any Hoehn and Yahr stage, a ROMP-Saliva C score of 11 or higher, ability to use the sensor, and no recent aspiration pneumonia, active drooling treatments, feeding tubes, or certain allergies.
- Who can participate?
- Participants must be at least 22 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 3 trial is estimated to last approximately 1 year and 2 months.